Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Aquila Biopharmaceuticals Inc
Profile last edited on: 8/1/08      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1999
First Award
2000
Latest Award
2001
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3 Forbes Road
Lexington, MA 02421
   N/A
   N/A
   N/A
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

In November 2000 Antigenics Inc. (Nasdaq: AGEN) of New York acquired Aquila Biopharmaceuticals, Inc. (Nasdaq: AQLA). Antigenics is working to develop personalized immunotherapeutics and revolutionary treatments for cancers, infectious diseases and autoimmune disorders. The company’s lead product candidate is Oncophage, a late-stage, personalized cancer vaccine being evaluated in several indications, including renal cell carcinoma and metastatic melanom

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$530,530
Phase II Dollars
$0
Total Awarded
$530,530

Synopsis: Awardee Business Condition

Employee Range
150-249
Revenue Range
15M-20M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2001 1 NIH $302,541
Project Title: A P. Falciparum MSP1 p42/QS-21 Malaria Vaccine
2000 1 NIH $100,000
Project Title: Lipid-Based Vaccines For Staphylococcus Aureus
2000 1 NIH $127,989
Project Title: CD1 Presented Vaccines to Prevent Chlamydia Infection

Key People / Management

  Gerald A Beltz

  Sandra P Chang

Company News

There are no news available.